Kronos Bio Inc. (KRON): Price and Financial Metrics

Kronos Bio Inc. (KRON): $2.56

0.19 (+8.02%)

POWR Rating

Component Grades













Add KRON to Watchlist
Sign Up

Industry: Biotech



in industry

KRON Stock Price Chart Interactive Chart >

Price chart for KRON

KRON Price/Volume Stats

Current price $2.56 52-week high $9.51
Prev. close $2.37 52-week low $1.35
Day low $2.30 Volume 322,300
Day high $2.62 Avg. volume 420,283
50-day MA $1.95 Dividend yield N/A
200-day MA $3.52 Market Cap 145.66M

Kronos Bio Inc. (KRON) Company Bio

Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib, a selective inhibitor targeting spleen tyrosine kinase in acute myeloid leukemia patients. The company is also developing KB-0742, an orally bioavailable inhibitor of cyclin dependent kinase 9 for the treatment of MYC-amplified solid tumors. Kronos Bio, Inc. is founded in 2017 and is headquartered in San Mateo, California.

KRON Latest News Stream

Event/Time News Detail
Loading, please wait...

KRON Latest Social Stream

Loading social stream, please wait...

View Full KRON Social Stream

Latest KRON News From Around the Web

Below are the latest news stories about KRONOS BIO INC that investors may wish to consider to help them evaluate KRON as an investment opportunity.

Deals, data kick off biotech's big JPM Week

Biotech companies are trying to get in front of investors and potential partners — and regulators — with news ahead of the big J.P. Morgan Healthcare Conference in San Francisco.

Yahoo | January 9, 2023

Kronos Bio’s stock rallies after announcing drug-discovery deal with Roche

MARKET PULSE Shares of Kronos Bio Inc. (KRON) jumped 25% in premarket trading on Monday after the company announced a development deal with Roche Holding’s (CH:ROG) Genentech. Kronos has a drug discovery platform that will be used to support Genentech’s research in small-molecule drugs for cancer.

Yahoo | January 9, 2023

Kronos Bio Announces Discovery Collaboration with Genentech to Advance Novel Therapies Against Transcriptional Targets in Oncology

Kronos Bio will receive a $20 million upfront payment and could receive up to an additional $554 million in milestone payments Agreement will leverage Kronos Bio’s expertise in transcriptional regulatory networks and its proprietary drug discovery platform SAN MATEO, Calif. and CAMBRIDGE, Mass., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, announced today that it has entered into a discovery collabor

Yahoo | January 9, 2023

Do investors need to be concerned about Kronos Bio Inc. (KRON)?

As of Friday, Kronos Bio Inc.’s (NASDAQ:KRON) stock closed at $1.49, up from $1.46 the previous day. While Kronos Bio Inc. has overperformed by 2.05%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, KRON fell by -90.32%, with highs and lows ranging from $15.80 to $1.40, […]

US Post News | December 26, 2022

We're Keeping An Eye On Kronos Bio's (NASDAQ:KRON) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Yahoo | December 20, 2022

Read More 'KRON' Stories Here

KRON Price Returns

1-mo 71.81%
3-mo -12.33%
6-mo -38.01%
1-year -71.43%
3-year N/A
5-year N/A
YTD 58.02%
2022 -88.08%
2021 -54.50%
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.5619 seconds.